I. COMMENCED TRADING IN DECEMBER

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%


INITIAL OFFERINGS

Affymax Inc.
(AFFY)1

7/28/06

12/15/06

4.255S

$25

14.87

Morgan Stanley & Co.,
Cowen and Co.,
Thomas Weisel Partners,
RBC Capital Markets

$106.4

$371.8

Newron
Pharmaceuticals
SpA
(Italy;
SWX:NWRN)2

11/20/06

12/8/06

2.147S

CHF55($45.65)

5.82S

Lehman Brothers, Morgan Stanley (co-lead), Bank Vontobel, Sal.Oppenheim

CHF118.1
($98.5)

CHF320.1
($264)

Pacgen Bio-
pharmaceuticals
Corp.
(Canada;
CDNX:PGA)3

11/28/06

12/8/06

6.789S and 3.4W

C$1.05

30.52

Canaccord Capital, Jennings Capital

C$7.13
($6.2)

C$32.0 ($27.8)

OVERALLOTMENT OPTIONS

Santhera
Pharmaceuticals
AG
(Switzerland;
SWX:SANN)4

10/23/06

11/24/06

0.148S

CHF90

3.10

Deutsche Bank AG, Piper Jaffray, WestLB AG, Zurcher Kantonalbank

CHF13.3 ($10.9)

CHF278.9 ($230)

Total: $220.0M

Number of IPOs in December: 3

Average value of December IPOs: $70.37M

Number of IPOs in 2006: 32

Total raised in IPOs in 2006: $1,659.18M

Average value of IPOs in 2006: $51.85M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares Out (M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%


Advanced
Magnetics Inc.
(AMAG)5

8/11/06

12/7/06

2.103S

$62

14.05

Morgan Stanley & Co., UBS Securities (co-lead), Jefferies & Co., ThinkEquity Partners

$130.4

$871.1

Alnylam
Pharmaceuticals
Inc.
(ALNY)6

11/27/06

12/12/06

4.7S

$22

37.00

Banc of America

$103.4

$814.0

Arena
Pharmaceuticals
Inc.
(ARNA)7

11/28/06

12/8/06

13.225S

$13.21

60.68

CIBC World Markets, Cowen and Co. (co-lead), Piper Jaffray & Co. co-lead), Needham & Co., Leerink Swann & Co., Fortis Securities, Morgan Joseph & Co., Oppenheimer & Co.

$174.7

$801.5

Biopure
Corp.
(BPUR)8

12/7/06

12/8/06

28.35U

$0.64

77.72

Dawson James, Securities

$18.1

$49.7

MannKind
Corp.
(MNKD)9

11/27/06

12/7/06

23S

$17.42

72.90

JP Morgan Securities, Merrill Lynch & Co. (co-lead), Wachovia Capital Markets, CIBC World Markets, Leerink Swann & Co.

$400.7

$1,270.0

Omrix Bio-
pharmaceuticals
Inc.
(OMRI)10

12/4/06

12/15/06

1.5S

$32

16.39

UBS Investment Bank, Citigroup (co-lead), CIBC World Markets, Rodman & Renshaw

$48

$524.5

Total: $875.3M

Number of follow-on offerings in December: 6

Average value of December follow-ons: $145.88M

Number of follow-on offerings in 2006: 40

Total raised in follow-ons in 2006: $4,967.67M

Average value of follow-ons in 2006: $124.19M


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal.

CDNX = Canadian Venture Exchange; SWX = Swiss Stock Exchange.

1. Affymax raised $106.4M in an IPO of 4.255M shares. Totals include the underwriters' purchase of 555,000 shares per their overallotment option.

2. Newron raised CHF118.1M an IPO on the Swiss Stock Exchange. Underwriters have an option to purchase up to 322,141 additional shares to cover overallotments.

3. Pacgen raised C$7.13M in an IPO on the Canadian Venture Exchange. Units consisted of one share and one-half a warrant; each whole, one-year warrant is exercisable at C$1.20 per share. Underwriters have an option to purchase up to about 1M additional units to cover overallotments.

4. Underwriters of Santhera's IPO in November exercised their option late in November on about 0.148M additional shares. The IPO totaled about 1.132M shares and CHF101.8M in gross proceeds.

5. Advanced Magnetics raised about $130.4M in a follow-on offering of 2.103M shares. Underwriters have an option to purchase up to 315,450 additional shares to cover overallotments.

6. Alnylam raised $103.4M in a follow-on offering of 4.7M shares. The underwriter has an option to purchase up to 705,000 additional shares to cover overallotments.

7. Arena raised $174.7M in a follow-on offering of 13.225M shares. Totals include the underwriters' purchase of 1.725M shares per their overallotment option.

8. Biopure raised $18.1M in an offering of units consisting of 28.35M shares and 28.35M five-year warrants, which are exercisable at $0.80 per share. Totals include the underwriter's purchase of 3.35M units per its overallotment option.

9. MannKind raised $400.7M in a follow-on offering of 23M shares. Totals include the underwriters' purchase of 3M shares per their overallotment option.

10. Omrix raised $48M in a follow-on offering of 1.5M shares Totals do not include 0.75M shares sold by existing shareholders. Underwriters have an option to purchase up to 337,500 additional shares to cover overallotments.

II. FILED AND PENDING

Company
(Symbol/
Proposed
Symbol)#*

Date Filed

Shares/
Units
(M)

Price
Range

Shares
Out
(M)
@

Lead, Other
Underwriters

Value
(M)


INITIAL OFFERINGS

Light Sciences
Oncology Inc.
(LSON)1

4/21/06

5.25S

$14-$16

N/A

Cowen & Co., Wachovia Securities (co-lead), Jefferies & Co., Thomas Weisel Partners

$78.75

Molecular
Insight
Pharmaceuticals
Inc.
(MIPI)2

11/8/05

N/A

N/A

N/A

Piper Jaffray & Co., Cowen & Co. (co-lead), Oppenheimer & Co., Roth Capital Partners

$57.5

OncoGenex
Technologies
Inc.
(Canada;
OGXI; TSX:OGX)3

12/13/06

N/A

N/A

N/A

RBC Capital Markets, Needham & Co., Lazard Capital Markets, Canaccord Adams, Susquehanna Financial Group

$48

Optimer
Pharmaceuticals
Inc.
(OPTR)4

11/9/06

N/A

N/A

N/A

Piper Jaffray & Co., Jefferies & Co. (co-lead), JMP Securities, Rodman & Renshaw

$86.25

Orexigen
Therapeutics
Inc.
(OREX)5

12/16/06

N/A

N/A

N/A

Merrill Lynch & Co., JP Morgan Securities (co-lead), JMP Securities, Leerink Swann & Co.

$86.25

Perlegen
Sciences Inc.
(PERL)6

4/10/06

N/A

N/A

N/A

Lehman Brothers, Deutsche Bank Securities (co-lead), Piper Jaffray & Co., Allen & Co.

$115

Pharmasset
Inc.
(VRUS)7

5/9/06

N/A

N/A

N/A

Banc of America Securities, UBS Investment Bank (co-lead), JMP Securities

$75

PTC
Therapeutics
Inc.
(PTCT)8

3/31/06

N/A

N/A

N/A

Morgan Stanley & Co., JP Morgan Securities (co-lead), Pacific Growth Equities

$86.25

Rosetta
Genomics Ltd.
(Israel; ROSG)9

9/7/06

3S

$11-$13

N.A

C.E. Unterberg, Towbin, Oppenheimer & Co., Maxim Group

$36

Sucampo
Pharmaceuticals
Inc.
(SCMP)10

6/19/06

N/A

N/A

N/A

Banc of America Securities, Deutsche Bank Securities (co-lead), Leerink Swann & Co.

$86.25

Synta
Pharmaceuticals
Corp.
(SNTA)11

11/22/06

N/A

N/A

N/A

Bear, Stearns & Co., Lehman Brothers (co-lead), Lazard Capital Markets, Montgomery & Co.

$115

FOLLOW-ON OFFERINGS

Aradigm Corp.
(ARDM)12

10/24/06

23S

$1.43

N/A

Punk Ziegel & Co.

$32.9


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

TSX = Toronto Stock Exchange.

1. Light Sciences Oncology filed to raise up to $86.25M in an IPO. The shares and price range were estimated in September. The value is based on the midpoint of those estimates.

2. Molecular Insight filed to raise up to $57.5M in an IPO.

3. OncoGenex filed to raise up to $48M in an IPO in both the U.S. and Canada.

4. Optimer filed to raise up to $86.25M in an IPO.

5. Orexigen filed to raise up to $86.25M in an IPO.

6. Perlegen filed to raise up to $115M in an IPO.

7. Pharmasset filed to raise up to $75M in an IPO.

8. PTC Therapeutics filed to raise up to $86.25M in an IPO.

9. Rosetta filed to raise $36M in an IPO on Nasdaq, based on the midpoint of the estimated price range.

10. Sucampo filed to raise up to $86.25M in an IPO.

11. Synta filed to raise up to $115M in an IPO. A previous IPO attempt was postponed in 2005.

12. Aradigm filed to sell up to 23M shares in a follow-on offering. The value is based on the Oct. 23 closing price.